Stephen Lam Chan, MBBS, MD (CUHK), FRCP, discusses the lack of benefit with adjuvant pembrolizumab in HCC following a complete radiologic response.
Stephen Lam Chan, MBBS, MD
Advertisement
Stephen Lam Chan, MBBS, MD, is a professor in the department of Clinical Oncology, The Chinese University of Hong Kong.
Articles by Stephen Lam Chan, MBBS, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
4
OncLive Weekly News Quiz (7/10/2026): Test Your Knowledge on Key Updates in Myeloma, MIBC, and More
5